Additionally, several of the differentially expressed genes are proposed to be potential therapeutic targets, such as FAIM2 in small cell lung carcinoma [18], ERRFI1 in pancreatic carcinoma [25], RASA4 in triple-negative breast carcinoma [53], FKBP10 in gliomas [7, 18], metastatic gastric carcinoma [16] and lung carcinoma [38], and CACNA2D in prostate carcinoma [18]. Here, ERRFI1 is linked to exocrine pancreatic carcinoma.